Lionco Pharmaceutical Group (603669.SH) issued a pre-loss warning, estimating a net loss of 120 million yuan for the year 2024.

Lionco Pharmaceutical Group (603669.SH) announced that it expects to achieve a net loss of approximately 120 million yuan attributable to the owners of the parent company in the annual report for the year 2024, a decrease of about 20.79% compared to the same period last year (statutory disclosure data). The main reason for the current period's loss is the decrease in gross profit caused by centralized procurement, with sales gross profit unable to cover current period expenses, resulting in a loss in performance for the period. During the reporting period, as the varieties of the centralized procurement gradually obtained market approvals and entered an upward cycle of market growth, the company increased its efforts to promote the varieties of the centralized procurement, leading to a significant increase in sales revenue compared to the same period last year. By fully utilizing channel advantages to promote non-centralized procurement varieties and expand the sales scale of these products, the company has increased market share, adjusted sales strategies, and added private hospital sales channels, resulting in a significant increase in sales revenue for cardiovascular and cerebrovascular products compared to the same period last year. Continuing to promote refined management, tap potential and reduce costs from various aspects, take effective measures to control costs and expenses; maximizing production capacity, fully leveraging production capacity advantages, actively seeking CMO orders, leading to a significant decrease in losses compared to the same period last year.